<DOC>
	<DOCNO>NCT00272766</DOCNO>
	<brief_summary>The purpose study evaluate safety effect visual acuity Macugen ( pegaptanib sodium ) patient subfoveal choroidal neovascularization ( CNV ) secondary ocular histoplasmosis syndrome ( OHS ) .</brief_summary>
	<brief_title>Macugen Histoplasmosis</brief_title>
	<detailed_description>Ocular histoplasmosis lead cause severe irreversible central vision loss middle-aged adult live central eastern US . OHS associate fungus Histoplasma capsulatum , dimorphic soil mold find 18 20 state central eastern US . Annually , approximately 100,000 people think risk vision loss cause OHS . This study include OHS patient CNV lesion large 5400 micron great linear diameter classic occult CNV extend geometric center FAZ best-corrected visual acuity letter score 20/40-20/200 . Twenty four patient enrol study 2 treatment arm 12 patient . The first arm consist 12 patient receive 0.3 mg Macugen intravitreally every 6 week one year . The second arm consist 12 patient receive Photodynamic Therapy ( PDT ) Visudyne every 3 month one year .</detailed_description>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Histoplasmosis</mesh_term>
	<criteria>Diagnosis ocular histoplasmosis , Evidence classic occult choroidal neovascularization extend geometric center fovea , Greatest linear diameter great 5400 micron , Bestcorrected visual acuity score 20/4020/200 , Ability give inform consent , Limited child bear potential negative pregnancy test Features condition OHS AMD , pathologic myopic angioid streak associate CNV study eye , Area CNV le 50 % total lesion include area prior laser treatment , previous rip retinal pigment epithelium , Vitelliformlike lesion , Telangiectasia , Central serous retinopathy , Serous pigment epithelial detachment without CNV , Any significant ocular disease CNV could compromise vision study eye , amblyopia , glaucoma , optic neuropathy , diabetic retinopathy , Inability obtain photographs document CNV , Presence atrophy/scar center fovea , Presence vitreoretinal traction center fovea , History treatment CNV study eye nonfoveal laser photocoagulation , within 12 week prior enrollment Participation another clinical trial use another investigational new drug within 12 week full extent study treatment , Intraocular surgery within last two month , Capsulectomy within last month study eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Ocular histoplasmosis</keyword>
	<keyword>Macugen</keyword>
	<keyword>Photodynamic therapy Visudyne</keyword>
	<keyword>Best-corrected visual acuity score 20/40-20/200</keyword>
	<keyword>classic occult choroidal neovascularization</keyword>
</DOC>